ACTRN12624000725561尚未招募1 期
A Phase 1 Randomized, Double-Blind, Dose- Escalating Study to assess the Safety, Tolerability, and Pharmacokinetics of MTX-474 in Healthy Adults
Mediar Therapeutics0 个研究点目标入组 80 人开始时间: 2024年6月13日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomised controlled trial
- 主要目的
- Treatment
- 盲法
- Blinded (masking used)
入排标准
- 年龄范围
- 18 Years 至 60 Years（—）
- 性别
- All
入选标准
- •All genders, ages 18 to 60 years, inclusive
- •- Consumption of not more than 5 cigarettes or other cotinine-containing products (including tobacco, nicotine gum, patches, and e-cigarettes) per week as long as they are willing to abstain nicotine use approximately 5 days prior to admission and during inpatient stays
- •- Willing to refrain from marijuana- or cannabinol-containing products for 30 days before Screening and until the last study visit
- •- Willing to refrain from ingestion of alcohol from 7 days before Screening until the last study visit
- •- Agrees to not donate egg or sperm (if applicable) from the time of first infusion until 125 days after the final dose; additionally agrees to not donate blood from 56 days prior to the time of first infusion until 90 days after the last study visit, or platelets/plasma 14 days prior to the time of first infusion until 90 days after the last study visit.
- •- All participants assigned female at birth must have a negative serum pregnancy test at Screening and a negative urine pregnancy test at Baseline.
- •- Participants are required to follow specific contraception measures as follows:
- •Participants assigned male at birth must use a condom (even if vasectomized) at the time of Screening and for 125 days after the final dose.
- •Participants assigned female at birth must be of non-childbearing potential (defined as either at least 6 months surgically sterilized or at least 1 year postmenopausal and confirmed by FSH (Follicle Stimulating Hormone) level >40U/L) OR, if of childbearing potential (defined as not sterilized via bilateral oophorectomy, or hysterectomy, ; still menstruating; or <1 year has passed since the last menses, if menopausal), must use a combination of 1 highly effective method of contraception and 1 effective method of contraception . This contraceptive practice should begin at least 28 days before the first dose of study drug, continue during the study, and persist for 65 days after the final dose of study drug, if applicable.
排除标准
- •Any concurrent active medical condition determined clinically significant by the Investigator
- •- Body mass index (BMI) >32 kg/m2.
- •- Use of any systemic immunosuppressant medications, medications to treat diabetes, antipsychotics, anticoagulants, or other prescription medications other than oral contraceptives within 90 days of Screening that, as determined by the Investigator, could confound their participation in the study
- •- Cancer or a history of cancer or lymphoproliferative disorder within 5 years of Screening other than adequately treated non-melanomatous skin cancers or cervical carcinoma in situ
- •- Current infection with hepatitis B, positive hepatitis B core antibody (HBcAb), hepatitis C, or human immunodeficiency virus (HIV) as evidenced by a positive hepatitis B surface antigen (HbsAg) at Screening or a positive HIV test at Screening. For hepatitis C, a positive hepatitis C antibody (anti-HCV) test is exclusionary unless the participant has previously been treated for hepatitis C, in which case they would be eligible with a negative HCV RNA.
- •- Currently pregnant, lactating, or planning to conceive or contribute to pregnancy during the trial and up to 28 days after the participant’s last dose of study drug, if applicable
- •- History of severe depression, psychosis, or suicidal ideation, as determined by the Investigator, within 5 years of Screening
- •-History of anaphylaxis or other significant allergies in the opinion of the Investigator.
- •- History of substance use disorder as specified in Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition, within 1 year of Screening
- •- Positive screen for drugs of abuse or alcohol intake at Screening or admission to the CRU (Day -1).
- •- Donation of blood within 28 days of Screening.
- •- Any clinically significant disease or laboratory abnormality detected at Screening that might interfere with a participant’s ability to complete the study, on-study evaluations, or participant safety, including the following:
- •Hemoglobin outside of the normal range for the study laboratory
- •Absolute neutrophils outside of the normal range for the study laboratory
- •White blood cells outside of the normal range for the study laboratory
- •Platelet count outside of the normal range for the study laboratory
- •- Any clinically significant abnormality on any of the screening ECGs
- •- Alanine aminotransferase or aspartate aminotransferase up to 1.2 times the upper limit of normal
- •- Any surgical procedure, including planned procedures within 12 weeks of Screening
- •- Participation in another research study of an investigational agent within 30 days of Screening or 5 half-lives of the agent, whichever is longer
研究者
相似试验
招募中
1 期
Phase 1 Dose Escalating, Double-Blind, Randomised Comparator Controlled Trial of the Safety and Immunogenicity of Different Adjuvant Formulations of R0.6C and ProC6C transmission blocking vaccines candidates against Plasmodium falciparum in Adults in Burkina Faso (TBVax1)MalariaPACTR202201848463189125
尚未招募
不适用
A Phase 1/2 Randomized, Blinded, Dose-escalation Study to Evaluate the Safety and Efficacy of Intrathecal Administration of AAV9-ABCD1 Gene Therapy (SBT101) in Adult Patients with AdrenomyeloneuropathyAdrenoleukodistrophydegenerative neurological disease10029317NL-OMON56436SwanBio Therapeutics, Ltd.5
招募中
不适用
A Phase 1, Randomized, Double-Blinded, Single-Dose Escalation Study Followed by a Multiple-Dose Escalation Study to Evaluate the Safety and Tolerability of SKL20540 in Healthy SubjectsMental and behavioral disordersKCT0002938SK Biopharmaceuticals92
已完成
1 期
A First in Human study in ascending doses of FDY-5301.acute myocardial infarctionACTRN12616001165471Clinical Network Services Pty Ltd40
进行中（未招募）
不适用
A Phase I/II, Double-Blind, Dose-Escalation Study to Evaluate the Safety and Antiviral Activity of IDX184 in Treatment-Naïve Subjects Infected with Genotype 1 Chronic Hepatitis Caïve Subjects Infected with Genotype 1 Chronic Hepatitis CMedDRA version: 9.1Level: LLTClassification code 10008912Term: Chronic hepatitis CEUCTR2008-005558-19-ATIdenix Pharmaceuticals, Inc.40